Intraventricular meningioma

Summary

Intraventricular meningioma (MONDO:0002772) is a disease. A subtype of cerebral ventricle cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	intraventricular meningioma
Mondo ID	MONDO:0002772
DOID	DOID:3772
NCIT	C5273
UMLS	C1334271
MedGen	232669
GARD	0023242
Anatomy (UBERON)	UBERON:0004086
Is cancer (heuristic)	no

Also known as: brain ventricle meningioma (disease) · meningioma (disease) of brain ventricle

Disease family

This is a subtype of cerebral ventricle cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › central nervous system cancer › brain cancer › cerebral ventricle cancer › intraventricular meningioma

Related subtypes (3): choroid plexus cancer, chordoid glioma of the third ventricle, central neurocytoma

Subtypes (2): choroid plexus meningioma, lateral ventricle meningioma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.